probucol has been researched along with Atrial Fibrillation in 9 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the underlying mechanisms for the increased propensity for AF in the setting of DM and the potential effects of probucol on atrial remodeling remain unclear." | 7.81 | Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-α/NF-κB/TGF-β signal transduction pathway in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Li, G; Li, J; Liu, C; Liu, T; Wang, X, 2015) |
| "We report a patient who experienced a reversible prolongation of the QT interval and episodes of syncope while receiving probucol." | 7.69 | Probucol-induced QT prolongation and syncope. ( Ito, M; Ohtsuka, E; Oribe, K; Oribe, M; Seita, M; Tamura, M; Ueki, Y, 1994) |
| "Probucol decreased the increase of CRP concentration and attenuated atrial oxidative stress caused by atrial tachypacing." | 5.35 | Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. ( Dong, DL; Gong, YT; Li, BX; Li, WM; Li, Y; Liu, W; Shan, HB; Sheng, L; Xue, HJ; Yang, BF; Yang, N; Yang, SS, 2009) |
| " However, the underlying mechanisms for the increased propensity for AF in the setting of DM and the potential effects of probucol on atrial remodeling remain unclear." | 3.81 | Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-α/NF-κB/TGF-β signal transduction pathway in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Li, G; Li, J; Liu, C; Liu, T; Wang, X, 2015) |
| "We report a patient who experienced a reversible prolongation of the QT interval and episodes of syncope while receiving probucol." | 3.69 | Probucol-induced QT prolongation and syncope. ( Ito, M; Ohtsuka, E; Oribe, K; Oribe, M; Seita, M; Tamura, M; Ueki, Y, 1994) |
| "Probucol decreased the increase of CRP concentration and attenuated atrial oxidative stress caused by atrial tachypacing." | 1.35 | Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. ( Dong, DL; Gong, YT; Li, BX; Li, WM; Li, Y; Liu, W; Shan, HB; Sheng, L; Xue, HJ; Yang, BF; Yang, N; Yang, SS, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Q | 1 |
| Liu, T | 5 |
| Ng, CY | 1 |
| Li, G | 5 |
| Fu, H | 3 |
| Liu, C | 2 |
| Li, J | 2 |
| Wang, X | 1 |
| Cheng, L | 2 |
| Ziolo, MT | 1 |
| Mohler, PJ | 1 |
| Shao, Q | 1 |
| Korantzopoulos, P | 1 |
| Ye, L | 1 |
| Liu, E | 1 |
| Xu, G | 1 |
| Yang, W | 1 |
| Tse, G | 1 |
| Zhao, J | 1 |
| Gong, YT | 1 |
| Li, WM | 1 |
| Li, Y | 2 |
| Yang, SS | 1 |
| Sheng, L | 2 |
| Yang, N | 1 |
| Shan, HB | 1 |
| Xue, HJ | 1 |
| Liu, W | 2 |
| Yang, BF | 1 |
| Dong, DL | 1 |
| Li, BX | 1 |
| Li, W | 1 |
| Gong, Y | 1 |
| Xue, H | 1 |
| Shan, H | 1 |
| Tamura, M | 1 |
| Ueki, Y | 1 |
| Ohtsuka, E | 1 |
| Oribe, M | 1 |
| Seita, M | 1 |
| Oribe, K | 1 |
| Ito, M | 1 |
1 review available for probucol and Atrial Fibrillation
| Article | Year |
|---|---|
Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Atr | 2014 |
1 trial available for probucol and Atrial Fibrillation
| Article | Year |
|---|---|
Effects of probucol on left atrial remodeling in patients with paroxysmal atrial fibrillation.
Topics: Aged; Anticholesteremic Agents; Atrial Fibrillation; Atrial Remodeling; Female; Follow-Up Studies; H | 2016 |
7 other studies available for probucol and Atrial Fibrillation
| Article | Year |
|---|---|
Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-α/NF-κB/TGF-β signal transduction pathway in alloxan-induced diabetic rabbits.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atrial Fibrillation; Atrial Remodeling; Biomarkers; | 2015 |
Defining the role of oxidative stress in atrial fibrillation and diabetes.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atrial Fibrillation; Atrial Remodeling; Diabetes Me | 2015 |
Probucol prevents atrial ion channel remodeling in an alloxan-induced diabetes rabbit model.
Topics: Action Potentials; Alloxan; Animals; Anti-Arrhythmia Agents; Antioxidants; Atrial Fibrillation; Atri | 2016 |
Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing.
Topics: Animals; Antioxidants; Atrial Fibrillation; Blotting, Western; C-Reactive Protein; Cardiac Pacing, A | 2009 |
Probucol and succinobucol in atrial fibrillation: pros and cons.
Topics: Anticholesteremic Agents; Atrial Fibrillation; Humans; Probucol | 2010 |
Probucol attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in dogs.
Topics: Animals; Antioxidants; Apoptosis; Atrial Fibrillation; bcl-2-Associated X Protein; Calpain; Caspase | 2009 |
Probucol-induced QT prolongation and syncope.
Topics: Atrial Fibrillation; Diltiazem; Electrocardiography; Female; Humans; Hypercholesterolemia; Long QT S | 1994 |